Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences approved a new equity award for its Interim Chief Executive Officer and Chief Financial Officer, James Parslow, under its Amended and Restated Equity Incentive Plan. The grant consists of 100,000 shares of restricted stock, documented in a restricted stock award agreement dated April 21, 2026.
Of these shares, 7,000 vest immediately on the grant date. The remaining 93,000 shares will vest in three equal installments on each of the first, second, and third anniversaries of April 21, 2026. This structure is designed to tie Mr. Parslow’s compensation to ongoing service over several years.
PARSLOW JAMES F reported acquisition or exercise transactions in this Form 4 filing.
Xenetic Biosciences, Inc. reported that Interim CEO and CFO James F. Parslow received a grant of 100,000 shares of Common Stock as a restricted stock grant. The award was made at a stated price of $0.00 per share, indicating compensation rather than a market purchase.
According to the vesting terms, 7,000 shares vest on the grant date, and one-third of the remaining 93,000 shares will vest on each of the first, second, and third anniversaries of April 21, 2026. Following this grant, Parslow directly holds 100,000 shares of Xenetic Biosciences common stock.
Xenetic Biosciences reported a full-year 2025 net loss of approximately $2.7 million, as it continued investing in its DNase-based immuno-oncology programs targeting difficult-to-treat cancers. Royalty revenue from its sublicense with Takeda grew about 19% to $3.0 million, up from $2.5 million in 2024.
Research and development expenses were $3.1 million, down from $3.3 million, partly because a $0.7 million impairment recorded in 2024 did not recur, while DNase process development spending increased. General and administrative costs fell about 20% to $2.7 million. Xenetic ended 2025 with roughly $7.9 million in cash, about $1.7 million higher than the prior year, primarily from net proceeds of around $4.0 million raised in an October 2025 underwritten public offering.
Xenetic Biosciences is an early-stage immuno-oncology company focused on DNase technology to improve treatment of difficult solid tumors, initially pancreatic and colorectal cancers. The approach targets neutrophil extracellular traps that contribute to tumor growth and resistance to chemotherapy, radiotherapy and immunotherapy.
The company is advancing a systemic DNase I program toward first-in-human studies and exploring DNase‑armored CAR T cells to improve cell therapy performance in solid tumors. Development is executed largely through external partners and academic collaborations, including Scripps Research, the University of Virginia, Catalent and PeriNess.
Xenetic has begun a formal strategic review, considering options such as a sale, asset sale or reverse merger, with outcomes that could significantly alter ownership. The business remains unprofitable, expects substantial additional funding needs, and currently generates modest royalties from a PolyXen out‑license to Takeda while prioritizing DNase over legacy platforms.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation filed a Schedule 13G reporting beneficial ownership of 178,509 shares of Xenetic Biosciences, Inc. common stock, representing 7.79% of the outstanding class.
They report sole voting and dispositive power over all 178,509 shares, with no shared power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Xenetic Biosciences.
Xenetic Biosciences, Inc. reported that its 2025 Annual Meeting of Stockholders, originally adjourned from December 11, 2025 to January 8, 2026 to seek more proxies and achieve a quorum, was again adjourned on January 8, 2026 without any business being conducted because a sufficient number of shares was not represented.
The company plans to reconvene the Annual Meeting at a future date and time that has not yet been set and will give stockholders the required advance notice before the new meeting.
Xenetic Biosciences, Inc. filed an 8-K announcing it furnished a press release with results for the three months ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference into Item 2.02.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act. The filing also includes customary forward-looking statements language outlining risk factors and cautions.
Xenetic Biosciences (XBIO) filed its Q3 2025 10‑Q, reporting royalty-driven revenue of $1,026,957 and a net loss of $509,940 (basic and diluted loss per share $0.33). Royalties stem from a sublicense with Takeda and rose versus last year.
Operating expenses included R&D $756,482 and G&A $815,209. Cash was $4,121,599 and total current liabilities were $1,111,775 as of September 30, 2025, reflecting continued focus on DNase research. Management believes existing resources fund operations for at least twelve months from issuance.
After quarter-end, the company completed an underwritten offering of 735,000 common shares at $6.12 per share, with estimated net proceeds of ~$3.9 million. Xenetic and its board began a strategic review considering alternatives, including a potential business combination or sale; the process has no set timetable and outcomes are uncertain. Common shares outstanding were 2,291,056 as of November 7, 2025.
Xenetic Biosciences is holding its virtual-only Annual Meeting on December 11, 2025 at 10:00 a.m. ET. Stockholders will vote on three items: elect six directors, ratify CBIZ CPAs P.C. as the independent auditor for fiscal year ending December 31, 2025, and approve, by non-binding advisory vote, the compensation of named executive officers.
The record date is October 15, 2025, with 2,277,139 shares outstanding and entitled to vote. A quorum requires 1,138,570 shares present or represented by proxy. Voting is available online before the meeting and during the webcast using the control number. The Board recommends voting FOR all proposals.
CBIZ was engaged as auditor following CBIZ’s acquisition of Marcum LLP’s attest business; Marcum resigned on April 8, 2025. Audit fees billed by Marcum were $160,000 in 2024 and $168,228 in 2023; audit-related fees were $5,000 in 2024 and $20,342 in 2023. The nominated directors include Grigory Borisenko, Firdaus Jal Dastoor, Dmitry Genkin, Roger Kornberg, Moshe Mizrahy, and Alexey Vinogradov.